Cargando…

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema

RATIONALE: Patients with combined pulmonary fibrosis and emphysema (CPFE) may develop acute exacerbations of IPF (AE-IPF) or COPD (AE-COPD). The incidence and the characteristics of exacerbations in patients with CPFE (e.g., COPD vs IPF) have not been well described. OBJECTIVES: To compare the incid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zantah, Massa, Dotan, Yaniv, Dass, Chandra, Zhao, Hauqing, Marchetti, Nathaniel, Criner, Gerard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325151/
https://www.ncbi.nlm.nih.gov/pubmed/32605574
http://dx.doi.org/10.1186/s12931-020-01432-x
_version_ 1783552097978941440
author Zantah, Massa
Dotan, Yaniv
Dass, Chandra
Zhao, Hauqing
Marchetti, Nathaniel
Criner, Gerard J.
author_facet Zantah, Massa
Dotan, Yaniv
Dass, Chandra
Zhao, Hauqing
Marchetti, Nathaniel
Criner, Gerard J.
author_sort Zantah, Massa
collection PubMed
description RATIONALE: Patients with combined pulmonary fibrosis and emphysema (CPFE) may develop acute exacerbations of IPF (AE-IPF) or COPD (AE-COPD). The incidence and the characteristics of exacerbations in patients with CPFE (e.g., COPD vs IPF) have not been well described. OBJECTIVES: To compare the incidence and rate of exacerbations in patients with CPFE vs. IPF and evaluate their effect on clinical outcomes. METHODS: Comprehensive clinical data from CPFE and IPF patients were retrospectively reviewed. Baseline characteristics including lung function data, oxygen requirements, and pulmonary hemodynamics, were collected. Acute exacerbation events in both groups were defined clinically and radiographically. In the CPFE group, two patterns of exacerbations were identified. AE-COPD was defined clinically by symptoms of severe airflow obstruction causing respiratory failure and requiring hospitalization. Radiographic data were also defined based on previously published literature. AE-IPF was defined clinically as an acute hypoxic respiratory failure, requiring hospitalization and treatment with high dose corticosteroids. Radiographically, patients had to have a change in baseline imaging including presence of ground-glass opacities, interlobular septal thickening or new consolidations; that is not fully explained by other etiologies. RESULTS: Eighty-five CPFE patients were retrospectively compared to 112 IPF patients. Of 112 patients with IPF; 45 had AE-IPF preceding lung transplant (40.18%) compared to 12 patients in the CPFE group (14.1%) (p < 0.05). 10 patients in the CPFE group experienced AE-COPD (11.7%). Patients with AE-IPF had higher mortality and more likely required mechanical ventilation and extracorporeal membrane oxygenation (ECMO) compared to patients with AE-COPD, whether their underlying disease was IPF or CPFE. CONCLUSIONS: CPFE patients may experience either AE-IPF or AE-COPD. Patients with CPFE and AE-COPD had better outcomes, requiring less intensive therapy compared to patients with AE-IPF regardless if underlying CPFE or IPF was present. These data suggest that the type of acute exacerbation, AE-COPD vs AE-IPF, has important implications for the treatment and prognosis of patients with CPFE.
format Online
Article
Text
id pubmed-7325151
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73251512020-06-30 Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema Zantah, Massa Dotan, Yaniv Dass, Chandra Zhao, Hauqing Marchetti, Nathaniel Criner, Gerard J. Respir Res Research RATIONALE: Patients with combined pulmonary fibrosis and emphysema (CPFE) may develop acute exacerbations of IPF (AE-IPF) or COPD (AE-COPD). The incidence and the characteristics of exacerbations in patients with CPFE (e.g., COPD vs IPF) have not been well described. OBJECTIVES: To compare the incidence and rate of exacerbations in patients with CPFE vs. IPF and evaluate their effect on clinical outcomes. METHODS: Comprehensive clinical data from CPFE and IPF patients were retrospectively reviewed. Baseline characteristics including lung function data, oxygen requirements, and pulmonary hemodynamics, were collected. Acute exacerbation events in both groups were defined clinically and radiographically. In the CPFE group, two patterns of exacerbations were identified. AE-COPD was defined clinically by symptoms of severe airflow obstruction causing respiratory failure and requiring hospitalization. Radiographic data were also defined based on previously published literature. AE-IPF was defined clinically as an acute hypoxic respiratory failure, requiring hospitalization and treatment with high dose corticosteroids. Radiographically, patients had to have a change in baseline imaging including presence of ground-glass opacities, interlobular septal thickening or new consolidations; that is not fully explained by other etiologies. RESULTS: Eighty-five CPFE patients were retrospectively compared to 112 IPF patients. Of 112 patients with IPF; 45 had AE-IPF preceding lung transplant (40.18%) compared to 12 patients in the CPFE group (14.1%) (p < 0.05). 10 patients in the CPFE group experienced AE-COPD (11.7%). Patients with AE-IPF had higher mortality and more likely required mechanical ventilation and extracorporeal membrane oxygenation (ECMO) compared to patients with AE-COPD, whether their underlying disease was IPF or CPFE. CONCLUSIONS: CPFE patients may experience either AE-IPF or AE-COPD. Patients with CPFE and AE-COPD had better outcomes, requiring less intensive therapy compared to patients with AE-IPF regardless if underlying CPFE or IPF was present. These data suggest that the type of acute exacerbation, AE-COPD vs AE-IPF, has important implications for the treatment and prognosis of patients with CPFE. BioMed Central 2020-06-30 2020 /pmc/articles/PMC7325151/ /pubmed/32605574 http://dx.doi.org/10.1186/s12931-020-01432-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zantah, Massa
Dotan, Yaniv
Dass, Chandra
Zhao, Hauqing
Marchetti, Nathaniel
Criner, Gerard J.
Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
title Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
title_full Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
title_fullStr Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
title_full_unstemmed Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
title_short Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
title_sort acute exacerbations of copd versus ipf in patients with combined pulmonary fibrosis and emphysema
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325151/
https://www.ncbi.nlm.nih.gov/pubmed/32605574
http://dx.doi.org/10.1186/s12931-020-01432-x
work_keys_str_mv AT zantahmassa acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema
AT dotanyaniv acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema
AT dasschandra acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema
AT zhaohauqing acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema
AT marchettinathaniel acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema
AT crinergerardj acuteexacerbationsofcopdversusipfinpatientswithcombinedpulmonaryfibrosisandemphysema